Campbell's Beats Q3 EPS as Eli Lilly Obesity Drug Data Lifts LLY Shares at ADA Conference

The Quick Take

• Campbell's (CPB) beat Q3 adjusted EPS analyst estimates, sending shares higher ahead of the US market open
• Eli Lilly (LLY) shares rose after positive obesity drug presentations at the American Diabetes Association 2026 conference
• Citi analysts said their conviction on LLY remains firmly intact, citing incretin pipeline strength

The dual stock-mover narrative spans consumer staples and large-cap pharma, two sectors that have diverged sharply in 2026. Campbell's delivered a Q3 earnings beat amid persistent pricing power in the canned goods and packaged food category, which has benefited from ongoing consumer trade-down from fresh to shelf-stable products. Eli Lilly's ADA 2026 data drop continued the company's run as the most closely watched name in healthcare, with its incretin portfolio — anchored by Mounjaro and Zepbound — attracting scrutiny on efficacy, tolerability, and competitive positioning against rival Novo Nordisk's semaglutide franchise amid intense market share dynamics.

Campbell's earnings beat reaffirms that consumer staples pricing resilience holds even as discretionary spending softens, a positive read-through for peers like General Mills and ConAgra. For Lilly, Citi's unchanged conviction after ADA data is a meaningful near-term confidence signal: the incretin market is large enough that even incremental differentiation data can move LLY's multi-hundred-billion-dollar market cap significantly. Novo Nordisk is the direct peer to watch for capital-rotation flows, as any LLY-specific catalyst typically prompts comparative positioning between the two obesity-drug giants in global healthcare portfolios.

Campbell's Q4 guidance will be the next critical test — analysts will probe volume recovery versus price-driven growth, with private-label share gains from discount retailers a key risk to monitor. For Lilly, the next data catalyst after ADA is FDA review timelines for new GLP-1 indications spanning cardiovascular, kidney, and NASH applications, with decision windows extending into late 2026. The macro variable across both names is the consumer and healthcare spending split: a labour-market slowdown constrains food budgets while simultaneously reducing patient access to high-cost GLP-1 therapies, creating opposing demand pressures in adjacent consumer health markets.

Synthesized from 1 source.